Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis C and responses to therapy in Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Genetics and Molecular Biology |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572013000100004 |
Resumo: | Soroprevalence for Hepatitis C virus is reported as 2.12% in Northern Brazil, with about 50% of the patients exhibiting a sustained virological response (SVR). Aiming to associate polymorphisms in Killer Cell Immunoglobulin-like Receptors (KIR) with chronic hepatitis C and therapy responses we investigated 125 chronic patients and 345 controls. Additionally, 48 ancestry markers were genotyped to control for population stratification. The frequency of the KIR2DL2 and KIR2DL2+HLA-C Asp80 gene and ligand was higher in chronic infected patients than in controls (p < 0.0009, OR = 3.4; p = 0.001, OR = 3.45). In fact, KIR2DL3 is a weaker inhibitor of NK activity than KIR2DL2, which could explain the association of KIR2DL2 with chronic infection. Moreover, KIR2DS2 and KIR2DS2+HLA-C Asp80 (p < 0.0001, OR = 2.51; p = 0.0084, OR = 2.62) and KIR2DS3 (p < 0.0001; OR = 2.57) were associated with chronic infection, independently from KIR2DL2. No differences in ancestry composition were observed between control and patients, even with respect to therapy response groups. The allelic profile KIR2DL2/KIR2DS2/KIR2DS3 was associated with the chronic hepatitis C (p < 0.0001; OR = 3). Furthermore, the patients also showed a higher mean number of activating genes and a lower frequency of the homozygous AA profile, which is likely secondary to the association with non-AA and/or activating genes. In addition, the KIR2DS5 allele was associated with SVR (p = 0.0261; OR = 0.184).The ancestry analysis of samples ruled out any effects of population substructuring and did not evidence interethnic differences in therapy response, as suggested in previous studies. |
id |
SBG-1_5d075eaa9c23330ebb70e0ea92568cda |
---|---|
oai_identifier_str |
oai:scielo:S1415-47572013000100004 |
network_acronym_str |
SBG-1 |
network_name_str |
Genetics and Molecular Biology |
repository_id_str |
|
spelling |
Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis C and responses to therapy in BrazilHCVKIRHLA-Chepatitis CKIR2DL2Soroprevalence for Hepatitis C virus is reported as 2.12% in Northern Brazil, with about 50% of the patients exhibiting a sustained virological response (SVR). Aiming to associate polymorphisms in Killer Cell Immunoglobulin-like Receptors (KIR) with chronic hepatitis C and therapy responses we investigated 125 chronic patients and 345 controls. Additionally, 48 ancestry markers were genotyped to control for population stratification. The frequency of the KIR2DL2 and KIR2DL2+HLA-C Asp80 gene and ligand was higher in chronic infected patients than in controls (p < 0.0009, OR = 3.4; p = 0.001, OR = 3.45). In fact, KIR2DL3 is a weaker inhibitor of NK activity than KIR2DL2, which could explain the association of KIR2DL2 with chronic infection. Moreover, KIR2DS2 and KIR2DS2+HLA-C Asp80 (p < 0.0001, OR = 2.51; p = 0.0084, OR = 2.62) and KIR2DS3 (p < 0.0001; OR = 2.57) were associated with chronic infection, independently from KIR2DL2. No differences in ancestry composition were observed between control and patients, even with respect to therapy response groups. The allelic profile KIR2DL2/KIR2DS2/KIR2DS3 was associated with the chronic hepatitis C (p < 0.0001; OR = 3). Furthermore, the patients also showed a higher mean number of activating genes and a lower frequency of the homozygous AA profile, which is likely secondary to the association with non-AA and/or activating genes. In addition, the KIR2DS5 allele was associated with SVR (p = 0.0261; OR = 0.184).The ancestry analysis of samples ruled out any effects of population substructuring and did not evidence interethnic differences in therapy response, as suggested in previous studies.Sociedade Brasileira de Genética2013-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572013000100004Genetics and Molecular Biology v.36 n.1 2013reponame:Genetics and Molecular Biologyinstname:Sociedade Brasileira de Genética (SBG)instacron:SBG10.1590/S1415-47572013000100004info:eu-repo/semantics/openAccessVasconcelos,Janaina Mota deMóia,Lizomar de Jesus Maués PereiraAmaral,Ivanete do Socorro AbraçadoMiranda,Esther Castello Branco MelloCicaliseTakeshita,Louise YukariOliveira,Layanna Freitas deMendes,Lilian de Araújo MeloSastre,DanutaTamegão-Lopes,Bruna PedrosoPedroza,Larysse Santa Rosa de AquinoSantos,Sidney Emanuel Batista dosSoares,Manoel do Carmo PereiraAraújo,Marialva Tereza Ferreira deBandeira,Camila LucasSilva,Adriana Maria Paixão de Sousa daMedeiros,Zilene Lameira deSena,LeonardoDemachki,SamiaSantos,Eduardo José Melo doseng2013-02-28T00:00:00Zoai:scielo:S1415-47572013000100004Revistahttp://www.gmb.org.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||editor@gmb.org.br1678-46851415-4757opendoar:2013-02-28T00:00Genetics and Molecular Biology - Sociedade Brasileira de Genética (SBG)false |
dc.title.none.fl_str_mv |
Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis C and responses to therapy in Brazil |
title |
Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis C and responses to therapy in Brazil |
spellingShingle |
Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis C and responses to therapy in Brazil Vasconcelos,Janaina Mota de HCV KIR HLA-C hepatitis C KIR2DL2 |
title_short |
Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis C and responses to therapy in Brazil |
title_full |
Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis C and responses to therapy in Brazil |
title_fullStr |
Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis C and responses to therapy in Brazil |
title_full_unstemmed |
Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis C and responses to therapy in Brazil |
title_sort |
Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis C and responses to therapy in Brazil |
author |
Vasconcelos,Janaina Mota de |
author_facet |
Vasconcelos,Janaina Mota de Móia,Lizomar de Jesus Maués Pereira Amaral,Ivanete do Socorro Abraçado Miranda,Esther Castello Branco Mello CicaliseTakeshita,Louise Yukari Oliveira,Layanna Freitas de Mendes,Lilian de Araújo Melo Sastre,Danuta Tamegão-Lopes,Bruna Pedroso Pedroza,Larysse Santa Rosa de Aquino Santos,Sidney Emanuel Batista dos Soares,Manoel do Carmo Pereira Araújo,Marialva Tereza Ferreira de Bandeira,Camila Lucas Silva,Adriana Maria Paixão de Sousa da Medeiros,Zilene Lameira de Sena,Leonardo Demachki,Samia Santos,Eduardo José Melo dos |
author_role |
author |
author2 |
Móia,Lizomar de Jesus Maués Pereira Amaral,Ivanete do Socorro Abraçado Miranda,Esther Castello Branco Mello CicaliseTakeshita,Louise Yukari Oliveira,Layanna Freitas de Mendes,Lilian de Araújo Melo Sastre,Danuta Tamegão-Lopes,Bruna Pedroso Pedroza,Larysse Santa Rosa de Aquino Santos,Sidney Emanuel Batista dos Soares,Manoel do Carmo Pereira Araújo,Marialva Tereza Ferreira de Bandeira,Camila Lucas Silva,Adriana Maria Paixão de Sousa da Medeiros,Zilene Lameira de Sena,Leonardo Demachki,Samia Santos,Eduardo José Melo dos |
author2_role |
author author author author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Vasconcelos,Janaina Mota de Móia,Lizomar de Jesus Maués Pereira Amaral,Ivanete do Socorro Abraçado Miranda,Esther Castello Branco Mello CicaliseTakeshita,Louise Yukari Oliveira,Layanna Freitas de Mendes,Lilian de Araújo Melo Sastre,Danuta Tamegão-Lopes,Bruna Pedroso Pedroza,Larysse Santa Rosa de Aquino Santos,Sidney Emanuel Batista dos Soares,Manoel do Carmo Pereira Araújo,Marialva Tereza Ferreira de Bandeira,Camila Lucas Silva,Adriana Maria Paixão de Sousa da Medeiros,Zilene Lameira de Sena,Leonardo Demachki,Samia Santos,Eduardo José Melo dos |
dc.subject.por.fl_str_mv |
HCV KIR HLA-C hepatitis C KIR2DL2 |
topic |
HCV KIR HLA-C hepatitis C KIR2DL2 |
description |
Soroprevalence for Hepatitis C virus is reported as 2.12% in Northern Brazil, with about 50% of the patients exhibiting a sustained virological response (SVR). Aiming to associate polymorphisms in Killer Cell Immunoglobulin-like Receptors (KIR) with chronic hepatitis C and therapy responses we investigated 125 chronic patients and 345 controls. Additionally, 48 ancestry markers were genotyped to control for population stratification. The frequency of the KIR2DL2 and KIR2DL2+HLA-C Asp80 gene and ligand was higher in chronic infected patients than in controls (p < 0.0009, OR = 3.4; p = 0.001, OR = 3.45). In fact, KIR2DL3 is a weaker inhibitor of NK activity than KIR2DL2, which could explain the association of KIR2DL2 with chronic infection. Moreover, KIR2DS2 and KIR2DS2+HLA-C Asp80 (p < 0.0001, OR = 2.51; p = 0.0084, OR = 2.62) and KIR2DS3 (p < 0.0001; OR = 2.57) were associated with chronic infection, independently from KIR2DL2. No differences in ancestry composition were observed between control and patients, even with respect to therapy response groups. The allelic profile KIR2DL2/KIR2DS2/KIR2DS3 was associated with the chronic hepatitis C (p < 0.0001; OR = 3). Furthermore, the patients also showed a higher mean number of activating genes and a lower frequency of the homozygous AA profile, which is likely secondary to the association with non-AA and/or activating genes. In addition, the KIR2DS5 allele was associated with SVR (p = 0.0261; OR = 0.184).The ancestry analysis of samples ruled out any effects of population substructuring and did not evidence interethnic differences in therapy response, as suggested in previous studies. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572013000100004 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572013000100004 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S1415-47572013000100004 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Genética |
publisher.none.fl_str_mv |
Sociedade Brasileira de Genética |
dc.source.none.fl_str_mv |
Genetics and Molecular Biology v.36 n.1 2013 reponame:Genetics and Molecular Biology instname:Sociedade Brasileira de Genética (SBG) instacron:SBG |
instname_str |
Sociedade Brasileira de Genética (SBG) |
instacron_str |
SBG |
institution |
SBG |
reponame_str |
Genetics and Molecular Biology |
collection |
Genetics and Molecular Biology |
repository.name.fl_str_mv |
Genetics and Molecular Biology - Sociedade Brasileira de Genética (SBG) |
repository.mail.fl_str_mv |
||editor@gmb.org.br |
_version_ |
1752122385367040000 |